Clinical Trials
12 trialsNCT02220985 2026-06-01
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01774630 2026-05-26
NiloPost-STIM
University Hospital, Bordeaux
Phase 2 Completed
NCT01343173 2026-05-19
STIM 2
University Hospital, Bordeaux
Phase NA Completed
NCT00720785 2026-05-07
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01231412 2026-04-30
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT05972577 2026-04-06
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT03874858 2026-04-02
DANTE
Novartis
Phase 2 Completed
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT01758042 2026-03-06
BMT
Massachusetts General Hospital
Phase NA Completed